Orchard Rx Ltd

Orchard Therapeutics plc (https://www.orchard-tx.com/) is a biopharmaceutical company. The Company is engaged in development, manufacturing and commercialization of gene and cell therapies to provide curative therapies to patients suffering from a range of diseases. It is focused on its autologous ex vivo autologous hematopoietic stem cell (HSC) gene therapy approach in approximately three therapeutic disease areas: neurodegenerative, immunological and blood disorders. Its portfolio includes over two commercial-stage products approved in Europe, seven lentiviral-based product candidates in clinical stage development and several other product candidates in preclinical development. The Company’s lead programs are OTL-200, which was approved in the European Union, United Kingdom, Iceland, Liechtenstein and Norway under the brand name Libmeldy for eligible patients with early onset metachromatic leukodystrophy (MLD), and OTL-103, which is being investigated for the treatment of Wiskott Aldrich syndrome (WAS).

• Orchard Rx Ltd